Abstract
INTRODUCTION
Thymic malignancies are a rare entity, and treatment practices are heterogeneous [1] . While certain factors such as complete resection with microscopically negative margins, Masaoka stage, tumour size and a histological classification of the World Health Organization (WHO) are generally accepted as prognostic markers for recurrence and survival, the optimal choice and sequencing of treatment modalities remain controversial [2] [3] [4] [5] [6] [7] [8] [9] . There is general consensus that early stage thymoma is best treated with surgical resection; however, the management of locally advanced and higher-grade tumours, including thymic carcinomas, remains controversial due to the lack of high-quality evidence [10] [11] [12] . This equipoise is reflected by the significant variability in therapeutic approaches between centres [1, 12] .
In locally advanced disease, surgical resection is often employed as part of the management of newly diagnosed disease, but it is variably applied in the relapsed setting [13, 14] . In addition, chemotherapy and radiation are combined in various neoadjuvant or postoperative regimens, largely based on consensus recommendations derived from retrospective series and single-arm prospective studies [4, 10, 11, [15] [16] [17] .
The approach at the Princess Margaret Cancer Centre has been relatively aggressive, where pleural and parenchymal recurrences (Stage IVa) are treated with surgical resection when feasible, combined with induction or adjuvant chemotherapy and/or radiation. In eligible candidates, such an aggressive local therapy is employed, especially if induction systemic therapy has induced a significant response. In select cases, recurrent tumours are even repeatedly surgically debulked after multiple relapses. One rationale for this management is that certain patients appear to have an indolent disease course with a tendency for late recurrences and favourable overall prognosis [18] . Conversely, in this setting, some authors question the use of aggressive combined systemic and local therapies as they can potentially lead to debilitating chronic treatment-related toxicities as well as poor healthrelated quality of life (HRQOL) [13, [19] [20] [21] [22] [23] .
The aim of this study is 2-fold: (i) to determine the impact of different multimodality regimens on health utility scores (HUS) and HRQOL in patients with locally advanced thymic malignancies and (ii) to describe symptom burden according to treatment modality to further explain any potential discordance in overall HRQOL.
METHODS AND MATERIALS

Study population
Individuals diagnosed with thymic malignancies were identified from thoracic oncology outpatient clinics in a comprehensive cancer centre. All patients with this disease were followed in a longitudinal multi-disciplinary clinic in which study subjects were regularly recruited. Those aged > _18 year with locally advanced disease (defined as Masaoka Stage II-IVa) and any WHO histology were approached between 2014 and 2017 to complete self-administered questionnaires. Patients diagnosed within the last month and those evaluated prior to the treatment initiation were excluded with further subset analyses of those diagnosed at least 1 year prior to HRQOL assessment. After enrolment, additional disease and treatment-related data were abstracted from medical records.
Study questionnaires
Participants answered a questionnaire consisting of demographic and health questions, the EuroQol 5 Dimensions (EQ-5D) with a visual analogue scale (VAS) [24] and patient self-reported Eastern Cooperative Oncology Group (ECOG) performance status and Edmonton Symptom Assessment Scale (ESAS) [25] scales. Questionnaires were administered on paper or via a handheld tablet and repeated at every medical visit. Because our focus was on the long-term effects of therapy, where there were multiple assessments in patients, we selected the most recent HUS and symptom assessment.
EQ-5D with VAS is a standardized validated tool that measures five spheres of HRQOL, including mobility, self-care, usual activities, pain and mood, grading each on a scale from 1 to 3 of increasing dysfunction [24] . The VAS ranks overall health from 0 to 100, where 100 represents perfect health. The results were subsequently converted into HUS using Canadian-specific metrics [26] . ESAS is a validated numerical scale ranging from 0 to 10 from the absence of symptoms to worse severity that explores nine common cancer-related complaints, including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing and shortness of breath [25] .
Statistical analysis
We first described overall HRQOL in survivors of thymic malignancies at our centre by reporting medians and frequencies of scores on the standardized measurement tools, such as EQ-5D, VAS and ECOG. Patient-reported ESAS scores were also collected to explore symptom burden. We then determined the impact of a multimodality therapy on HRQOL by comparing the EQ-5D with VAS and self-reported ECOG performance status in patients treated with trimodality versus uni-or bimodality regimens. Trimodality regimens included any combination of chemotherapy, radiation and surgical resection with curative intent as the initial management of disease, while uni-or bimodality therapy was defined as all other upfront treatments. We further examined the effect of an initial treatment approach in patients treated at >1 year after diagnosis to highlight chronic symptoms that could occur once therapy was completed.
Finally, to assess the impact of multiple surgical resections on HRQOL in the setting of recurrent disease, we compared those who underwent aggressive approaches (defined as reresection of metastatic disease ± chemotherapy and radiation) to those who were treated with palliative modalities (defined as palliative radiation, surgery such as pleurodesis and/or chemotherapy) or observation alone after relapse and those without recurrence.
Baseline patient and treatment-related characteristics were compared between groups using the v 2 and Wilcoxon rank-sum tests for categorical and numeric variables, respectively. The Kruskal-Wallis analysis was performed as a non-parametric test to compare groups in terms of approach to recurrent disease. Linear regression analysis was used to investigate the association between initial treatment modalities and management of relapse on HUS. Univariable and multivariable analyses exploring potential confounders were also performed using generalized linear models. Confidence intervals were computed using a generalized linear model, and normal distribution was assumed. Residual analyses were performed for both models; while many of the univariable models did not fulfil the assumption of normal distribution for HUS, the multivariable one did. Sensitivity analyses were also completed for both models without a significant impact on the results. P-values of <0.05 were considered statistically significant. All statistics were conducted on SASv9.2. Our study was approved by the ethics review board of the University Health Network.
RESULTS
Patient demographics
Among the patients approached for study participation, recruitment rate was 88%. Of the 97 patients who completed the questionnaires, 22 were excluded from the current study because of ineligible Stage (I or IVb) while 3 were not analysed as they had only provided pretreatment data. Of the remaining 72 eligible patients, 43 (60%) were male with a median age of 58 years, and 65 (90%) had thymoma while 7 (10%) had thymic carcinoma (Table 1) . Median time since diagnosis was 50.5 months (range 3-266) and median time since last treatment was 32.5 months (range 0-266), including therapy at diagnosis or in the relapsed setting. Sixty-four patients (89%) who completed questionnaires were diagnosed >1 year ago, and in this subgroup, the median time since diagnosis was 55 months (range 13-266).
Baseline characteristics were balanced between groups with the exception of higher stage of disease at diagnosis and higher rate of recurrent disease in those initially treated with the trimodality therapy ( Table 1 ). In the subgroup of patients diagnosed over a year ago, those treated with the trimodality therapy also had a shorter time between diagnosis and completion of questionnaires (47.5 vs 66 months, respectively, P = 0.03).
Initial therapy
Trimodality regimens included various induction, adjuvant or perioperative treatments combined with surgical resection (n = 24). Most common approaches were neoadjuvant chemoradiation with or without adjuvant chemotherapy followed by surgery (n = 11) and induction chemotherapy followed by surgery and adjuvant radiation (n = 8). Remaining patients were treated with sequential preoperative chemotherapy and radiation (n = 3) followed by surgery and upfront surgery with adjuvant sequential (n = 1) or concurrent chemotherapy and radiation (n = 1). Platinum and etoposide doublets were the most commonly used chemotherapy regimens both alone and in combination with radiation (n = 18), while alternatives included cisplatin, adriamycin and cyclophosphamide (n = 4), carboplatin and paclitaxel (n = 1) and single-agent cisplatin (n = 1). The majority of patients in the uni-or bimodality group underwent surgical resection followed by adjuvant radiation (n = 29) or surgery alone (n = 9) as initial management. Other approaches included chemotherapy alone (n = 3), concurrent chemoradiation (n = 3), radiation followed by chemotherapy (n = 1) or vice versa (n = 1), induction chemotherapy followed by surgery (n = 1) and radiation alone (n = 1). In those treated with any chemotherapy, platinum and etoposide doublet (n = 5) or cisplatin, adriamycin and cyclophosphamide (n = 4) was administered.
The vast majority of patients treated underwent surgical resection as part of initial management (100% trimodality vs 88% uni-or bimodality, respectively, P = 0.26), and in about half of surgically resected tumours R0 status was achieved (54% vs 46%, respectively, P = 0.09; Table 2 ).
Recurrent disease and subsequent treatments
Overall, 24 patients presented with relapsed disease after initial therapy with curative intent. Of these patients, 12 underwent surgical intervention of recurrent disease, of which 10 were treated with aggressive therapy for at least one of their recurrences. Others were followed with expectant management (n = 7) or palliative approaches (n = 7), including one patient who underwent a pleurodesis and one who had a pleural nodule excisional biopsy.
Health utilities and symptoms
In the 72 patients with thymic malignancies, the median HUS score was 0.79 with a median VAS score of 80 and patientreported ECOG of 1 (Fig. 1A and Table 3 ). All patients reported minimal symptoms reflected by low symptom scores for each of the domains of ESAS (Fig. 2) . The most common complaints were mild tiredness, shortness of breath and impaired wellbeing with overall median scores of 2 on each scale.
In the subgroup of patients treated over 1 year ago at the time of evaluation, HUS, VAS and patient-reported ECOG were similarly favourable with median values of 0.81, 80 and 1, respectively (Table 3) . Table 3 ], and individual symptom scores on ESAS scales were also similar by the number of modalities of therapy ( Fig. 2A) .
HUS was also statistically similar in patients with aggressively treated recurrent disease (median value, 0.80) versus those treated with palliative modalities at relapse (0.76) and those without recurrence (0.83) (P = 0.26, Fig. 1B ). VAS and ECOG scores were also consistent across these patient groups (median VAS values of 80, 80 and 80, P = 0.74; median ECOG scores of 1, 1 and 1, P = 0.23, respectively). Symptoms were similar in groups and minor across the nine symptoms (Fig. 2B) .
In univariable and multivariable analyses, time since diagnosis and the use of multiple lines of chemotherapy were significantly associated with lower HUS, while age, gender, Carlson comorbidity index (CCI), stage at diagnosis, WHO histology, resection status, time since last treatment, recurrence status and the use of multiple surgeries were not (Table 4) .
DISCUSSION
This study reports detailed HRQOL in patients diagnosed with thymic malignancies from a centre that utilizes aggressive approaches to both initial therapy and recurrent disease. Furthermore, when patients are properly selected, an aggressive initial treatment approach, in addition to aggressive management at the time of relapse, can lead to long-term survivorship. What this study now demonstrates is that such survivors report favourable HRQOL as measured with various standardized measurement tools including HUS, VAS and ECOG scores, regardless of initial treatment modality or aggressiveness of approach to relapsed disease. Irrespective of management at diagnosis or at recurrence, survivors also benefitted from a low symptom burden throughout the course of their disease as evidenced by their individual ESAS item and average ESAS scores. Few studies have included QOL measurements in survivors of thymic malignancies, likely due to the rarity of this disease, and the requirement of a long duration of follow-up. Boldingh et al. [27] conducted a population-based cross-sectional study investigating HRQOL in patients diagnosed with myasthenia gravis and sought to identify potential prognostic factors. They found that the presence of thymoma was not predictive of worse HRQOL despite a more aggressive disease course and a greater use of immunosuppressant drugs. Busch et al. [28] investigated the impact of thymectomy on disease course and QOL in patients with MG. They reported nearly complete restoration to baseline status in terms of physical, working, cognitive and social abilities after long-term follow-up of this procedure, and they found that thymic pathology was not predictive of long-term HRQOL.
Multiple studies have reported on HRQOL in other thoracic malignancies, in particular non-small-cell lung cancer (NSCLC). Grutters et al. [29] examined this outcome using the EQ-5D score in NSCLC survivors and reported only slightly lower median utility scores compared to the general population (median HUS 0.74, SD 0.27). They determined that the presence of severe adverse events (dyspnoea > _ Grade 3 as per the Common Terminology Criteria for Adverse Events) and initial treatment with combined chemotherapy and radiation were inversely associated with QOL in subgroup analyses. In a similar study, Trippoli et al. [30] found a slightly lower median HUS (0.58, SD 0.32). Contrary to Grutters et al., they determined that the presence of metastases was predictive of lower (worse) utility scores. Overall, many studies have sought to measure QOL in patients with NSCLC with various other standardized tools and have reported similar mean utility scores in the range of 0.6-0.75.
In our study, the reported HUS and VAS are overall favourable and slightly greater than those previously reported in patients with NSCLC. This would be expected given the better prognosis of thymic malignancies, a generally lower rate of comorbidities and the younger age of this population as represented by our study patients. These results are also in keeping with findings in which patients with myasthenia gravis and concurrent thymic malignancy reported similar outcomes as those without an underlying cancer, which suggested that HRQOL was mainly dictated by myasthenia gravis-related symptoms [29, 30] .
We also found that those treated with trimodality regimens upfront had similarly favourable QOL and long-term symptom burden as their counterparts treated more conservatively, despite a higher rate of recurrence and the use of multiple lines of chemotherapy as expected in this subgroup. This could in part be related to the selection bias of individuals with a greater baseline physical reserve fit for such aggressive therapy. However, age, CCI, rate of resection and re-resection were balanced between groups, and they were not found to be associated with worse HUS in our study, which suggested that confounding by baseline health status was not an overriding factor to explain the favourable QOL and symptom scores in trimodality patients. These results should, however, be interpreted with caution given the small number of patients in each treatment arm.
Multiple series have reported long-term survival with the aggressive treatment of recurrent disease along with acceptable operative safety [13, [18] [19] [20] [21] . Our data complement this body of research by demonstrating excellent long-term HRQOL in this population, even in those treated with multimodality interventions in the relapsed setting. In the multivariable analysis, longer time since diagnosis and the use of multiple lines of chemotherapy were associated with worse HUS, which could in part be related to the occurrence of recurrent disease requiring additional treatments and related declining performance status. Relatively, the magnitude of decline from time since diagnosis was quite different than the effect of having multiple lines of chemotherapy, whereby it would take 8.1 years difference in time since diagnosis to be equivalent to having the same difference as having multiple versus one line of chemotherapy.
Limitations
Our study's main limitations are its single-centre retrospective cross-sectional nature. This design results in survivorship bias, but given that our study question pertains to QOL in long-term survivors, it implies exclusion of early disease or treatment-related deaths and the results should be interpreted accordingly. Another limitation is the relatively small number of patients. This constraint is however inherently related to thymic malignancies due to their rarity and indolent course. HRQOL reported in the overall population (n = 72) represents a significant number of cases given this disease; however, the lack of statistically significant differences in this outcome between treatment subgroups should be interpreted with caution given this limitation. Finally, the tools used to assess HRQOL were not specific to thymic malignancies, but given their inclusion of a wide variety of cancer-related symptoms, they likely provide reasonable estimates of this outcome.
CONCLUSION
In summary, multiple therapeutic options are currently available for the treatment of thymic malignancies. In this setting, oncological outcomes should be balanced against toxicity, HRQOL and economical considerations when choosing the optimal regimens for patients. Patients treated for thymic malignancies report favourable QOL, HUS and symptom profile, and these outcomes are independent of the number and type of initial modalities or management of recurrence. These findings support the use of multimodality regimens given the high rate of response to chemotherapy and radiation and potential for long disease-free interval with surgical resection in this disease.
